TITLE:
Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Metastatic Colorectal Cancer.

CONDITION:
Colorectal Neoplasms

INTERVENTION:
Vatalanib

SUMMARY:

      To compare treatment with oxaliplatin/5-FU/leucovorin plus vatalanib versus
      oxaliplatin/5-FU/leucovorin plus placebo in patients with colorectal cancer that has spread
      to other organs and are seeking first chemotherapy treatment
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion criteria:

          -  Patients with metastatic colorectal cancer coming for initial chemotherapy

          -  Documented metastatic colorectal cancer

          -  WHO Performance Status of 0, 1, or 2

          -  Measurable tumors

          -  Adequate hematologic status, liver and kidney function

          -  Life expectancy greater than 12 weeks

          -  Written informed consent obtained

        Exclusion criteria:

          -  History or presence of central nervous system disease

          -  Patients with a history of another primary cancer within 5 years

          -  Prior chemotherapy for metastatic colorectal cancer

          -  Prior full field radiotherapy within 4 weeks or limited field radiotherapy within 2
             weeks before entry to study

          -  Major surgery within 4 weeks or minor surgery within 2 weeks before entry to study

          -  Investigational drugs within 4 weeks before entry to study

          -  Prior therapy with anti-VEGF agents

          -  Any prior therapy with oxaliplatin or allergy to platinum-containing drugs

          -  Peripheral neuropathy with functional impairment

          -  Female patients who are pregnant or breast feeding

          -  Any severe or uncontrolled medical conditions which could prevent participation in
             study

          -  Patients who are taking Coumadin

        Other protocol-defined inclusion / exclusion criteria may apply
      
